Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relapse Prevention in Stimulant Use Disorder
NCT04553263Phase 1Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of naltrexone + bupropion and bupropion in stimulant use disorder (SUD) (3 arms), sponsored by University of California, Los Angeles. Primary endpoints: Stimulant use 1 month after leaving inpatient treatment (self-report) at 84 days and Stimulant use 1 month after leaving inpatient treatment (urine toxicology) at 84 days. Planned start Jun 2023; status: withdrawn.
02
Drugs
naltrexone + bupropionbupropion
03
Conditions
stimulant use disorder (SUD)
Beyond the preview
Go deeper on NCT04553263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553263.